The review synthesizes evidence on whether Alzheimer’s disease medications can improve neurocognitive outcomes in children and adolescents with autism and low IQ. Across 12 studies, preliminary findings show promising gains in language, executive function, learning and memory, and general cognitive ability, particularly in younger children.